Heterologous immunisation with vector vaccine as prime followed by mRNA vaccine as boost leads to humoral immune response against SARS-CoV-2, which is comparable to that according to a homologous mRNA vaccination scheme

Ruben Rose, Franziska Neumann, Olaf Grobe, Thomas Lorentz, Helmut Fickenscher, Andi Krumbholz
doi: https://doi.org/10.1101/2021.07.09.21260251

Article usage

Article usage: July 2021 to May 2025

AbstractFullPdf
Jul 202129081291319
Aug 202174052172
Sep 2021775108236
Oct 2021391148155
Nov 2021535128336
Dec 202156093527
Jan 202225053441
Feb 202213420115
Mar 20221651782
Apr 20221032935
May 202277734
Jun 2022961218
Jul 202267512
Aug 202252719
Sep 202271920
Oct 2022133510
Nov 202244213
Dec 202243718
Jan 202346516
Feb 2023461213
Mar 20233733
Apr 2023543191
May 202336414
Jun 20232453
Jul 202332310
Aug 2023651218
Sep 20231041030
Oct 202344421
Nov 202326119
Dec 20231667
Jan 20244655
Feb 2024117818
Mar 202473811
Apr 202417619
May 202429914
Jun 20242166
Jul 202418110
Aug 2024361234
Sep 202439314
Oct 202418413
Nov 202420417
Dec 202422219
Jan 202525820
Feb 2025241112
Mar 202534927
Apr 2025401524
May 202520816
Back to top
Posted July 13, 2021.
Download PDF
Data/Code
Email
Heterologous immunisation with vector vaccine as prime followed by mRNA vaccine as boost leads to humoral immune response against SARS-CoV-2, which is comparable to that according to a homologous mRNA vaccination scheme
Ruben Rose, Franziska Neumann, Olaf Grobe, Thomas Lorentz, Helmut Fickenscher, Andi Krumbholz
medRxiv 2021.07.09.21260251; doi: https://doi.org/10.1101/2021.07.09.21260251
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area